REVUE DE PRESSE
La MRD mais pourquoi si tôt ?
Réf. :HematoStat.net ; 2 (7) : R52 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized [...]
Complications à long terme dans le Hodgkin
Réf. :HematoStat.net ; 2 (6) : R51 Lagerlöf I, Fohlin H, Enblad G, Glimelius B, Goldkuhl C, Palma M, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage [...]